Holen Sie sich die Stockscreener-App
8.63
5.89%
-0.54
Handel nachbörslich:
8.63
Schlusskurs vom Vortag:
$9.17
Offen:
$9.2
24-Stunden-Volumen:
682.21K
Relative Volume:
1.48
Marktkapitalisierung:
$494.21M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-96.66M
KGV:
-3.5809
EPS:
-2.41
Netto-Cashflow:
$-83.73M
1W Leistung:
-32.15%
1M Leistung:
-30.57%
6M Leistung:
-12.30%
1J Leistung:
-45.76%
1-Tages-Spanne:
$8.21
$9.485
1-Wochen-Bereich:
$8.21
$12.78
52-Wochen-Spanne:
$8.21
$16.77
Olema Pharmaceuticals Inc Stock (OLMA) Company Profile
Firmenname
Olema Pharmaceuticals Inc
Sektor
Branche
Telefon
(415) 651-3316
Adresse
780 BRANNAN STREET, SAN FRANCISCO
Vergleichen Sie OLMA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| OLMA | 8.63 | 494.21M | 0 | -96.66M | -83.73M | -2.41 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Olema Pharmaceuticals Inc Stock (OLMA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-01-30 | Eingeleitet | Citigroup | Buy |
| 2023-07-21 | Eingeleitet | Oppenheimer | Outperform |
| 2023-05-05 | Eingeleitet | CapitalOne | Overweight |
| 2023-02-22 | Eingeleitet | Credit Suisse | Outperform |
| 2022-07-06 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-06-09 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2022-02-28 | Eingeleitet | H.C. Wainwright | Neutral |
| 2021-12-07 | Fortgesetzt | Cowen | Outperform |
| 2020-12-14 | Eingeleitet | Canaccord Genuity | Buy |
| 2020-12-14 | Eingeleitet | Cowen | Outperform |
| 2020-12-14 | Eingeleitet | JP Morgan | Overweight |
| 2020-12-14 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Olema Pharmaceuticals Inc Aktie (OLMA) Neueste Nachrichten
Olema Pharmaceuticals stock hits 52-week low at $8.51 - Investing.com
What is Lifesci Capital’s Estimate for OLMA FY2025 Earnings? - Defense World
Equities Analysts Issue Forecasts for OLMA FY2024 Earnings - Defense World
What is Lifesci Capital's Forecast for OLMA FY2025 Earnings? - MarketBeat
What is HC Wainwright's Estimate for OLMA FY2024 Earnings? - MarketBeat
Olema Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times
OLMAOlema Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Olema Oncology to Participate in Upcoming Investor Conferences - The Manila Times
Olema Oncology to Present at Three Major Healthcare Investor Conferences | OLMA Stock News - StockTitan
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Given Average Recommendation of “Buy” by Brokerages - Defense World
Brokerages Set Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) PT at $27.00 - MarketBeat
Here's Why We're Not Too Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Situation - Yahoo Finance
Possible Bearish Signals With Olema Pharmaceuticals Insiders Disposing Stock - Simply Wall St
SG Americas Securities LLC Acquires Shares of 13,056 Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
Olema Pharmaceuticals (NASDAQ:OLMA) Earns Buy Rating from HC Wainwright - MarketBeat
Olema Pharmaceuticals maintains Buy rating from H.C. Wainwright By Investing.com - Investing.com UK
Olema stock a buy as Goldman highlights promising preclinical data for KAT6 inhibitor - Investing.com UK
Olema Oncology Presents Compelling New Preclinical Data Demonstrating Anti-Tumor Activity for OP-3136 with Enhanced Activity of Palazestrant Combinations at ENA 2024 - The Manila Times
Insider Selling: Paradigm Biocapital Advisors L, Olema Pharmaceuticals Inc [OLMA] 10% Owner divested 2,400,000 shares – Knox Daily - Knox Daily
Closing Bell Recap: Olema Pharmaceuticals Inc (OLMA) Ends at 11.26, Reflecting a -1.23 Downturn - The Dwinnex
Can you still get a good price for Olema Pharmaceuticals Inc (OLMA) Shares at this point? - US Post News
Renaissance Technologies LLC Buys Shares of 53,200 Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat
Olema Oncology Announces New Preclinical Combination Data to be Presented at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics - The Manila Times
Point72 Asset Management L.P. Purchases New Holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat
Aurigene Oncology, Olema Pharmaceuticals identify KAT6A inhibitors - BioWorld Online
Brokerages Set Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Target Price at $27.00 - MarketBeat
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Shares Sold by Dimensional Fund Advisors LP - Defense World
OLMA Stock: A Comprehensive Analysis and Forecast - The InvestChronicle
OLMA underperforms with a -4.07 decrease in share price - US Post News
74,657 Shares in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Acquired by Dana Investment Advisors Inc. - MarketBeat
olema pharmaceuticals, inc. Earnings dates - RTTNews
Olema Pharmaceuticals (NASDAQ:OLMA) Shares Down 3.8% - MarketBeat
Keeping an Eye on Olema Pharmaceuticals Inc (OLMA) After Insider Trading Activity - Knox Daily
Insider’s View: Deciphering Olema Pharmaceuticals Inc (OLMA)’s Financial Health Through Ratios - The Dwinnex
Long Term Trading Analysis for (OLMA) - Stock Traders Daily
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Shares Purchased by Marshall Wace LLP - Defense World
Ensign Peak Advisors Inc Acquires 850 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
Affinity Asset Advisors LLC Purchases Shares of 275,000 Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
Affinity Asset Advisors LLC Invests $2.98 Million in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat
Rhumbline Advisers Buys 17,953 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Shares Sold by Logos Global Management LP - Defense World
Great Point Partners LLC Takes Position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
Great Point Partners LLC Purchases New Stake in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat
Examining the Potential Price Growth of Olema Pharmaceuticals Inc (OLMA) - Knox Daily
Olema Pharmaceuticals (NASDAQ:OLMA) Shares Up 6.3% - Defense World
Taking the lead: Olema Pharmaceuticals Inc (OLMA) - SETE News
A Tale of Resilience: Olema Pharmaceuticals Inc Amid Stock Market Turbulence - The InvestChronicle
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Position Boosted by Bank of New York Mellon Corp - MarketBeat
Bank of New York Mellon Corp Acquires 58,622 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
Finanzdaten der Olema Pharmaceuticals Inc-Aktie (OLMA)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):